Key Developments: Sangamo BioSciences Inc (SGMO.O)
8.18USD
18 Jun 2013
$0.19 (+2.38%)
$7.99
$7.91
$8.20
$7.84
489,581
702,037
$11.24
$4.77
Latest Key Developments (Source: Significant Developments)
Sangamo Biosciences Inc Announces New Data From In Vivo Protein Replacement Platform For Development Of ZFP Therapeutics For Monogenic Diseases
Sangamo Biosciences Inc announced the presentation of new data demonstrating the successful application of Sangamo's In Vivo Protein Replacement Platform (IVPRP) to produce therapeutically relevant levels of Factor VIII in a mouse model. Sangamo has partnered with Shire AG to develop ZFP Therapeutics for both hemophilia A and B using this approach. Based on Sangamo's zinc finger DNA-binding protein (ZFP) genome-editing technology, the IVPRP enables the permanent production of therapeutic proteins from the liver with a single systemic treatment, potentially providing curative treatments for a range of monogenic diseases including hemophilia and lysosomal storage disorders (LSD) such as Gaucher and Fabry disease. Such diseases are currently treated by regular infusions of protein or enzyme replacement therapy (ERT) throughout the patient's life. Data were presented on the production of Factors VIII and IX for the correction of hemophilia A and B, as well as four enzymes absent in a panel of LSDs by Sangamo's collaborators from the laboratory of Katherine A. High, M.D., director of the Center for Cellular and Molecular Therapeutics at The Children's Hospital of Philadelphia, and Investigator, Howard Hughes Medical Institute. Full Article
Sangamo Biosciences Inc Reiterates FY 2013 Revenue Guidance
Sangamo Biosciences Inc reiterated its fiscal 2013 guidance and expects revenues will be in the range of $20-$24 million , inclusive of research funding from Shire. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report revenue of $20 million for fiscal 2013. Full Article
Sangamo Biosciences Inc Issues FY 2013 Revenue Guidance In Line With Analysts' Estimates
Sangamo Biosciences Inc announced that for fiscal 2013, it expects revenues to be in the range of $20 to $24 million. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report revenue of $23 million for fiscal 2013. Full Article
Sangamo Biosciences Inc Raises FY 2012 Revenue Guidance
Sangamo Biosciences Inc announced that for fiscal 2012, it expects revenues to be in the range of $18 to $20 million, inclusive of research funding from Shire (earlier guidance was $14 to $18 million). According to I/B/E/S Estimates, analysts on an average are expecting the Company to report revenue of $17.63 million for fiscal 2012. Full Article
Sangamo BioSciences, Inc. Reaffirms FY 2012 Revenue Guidance
Sangamo BioSciences, Inc. reiterated fiscal 2012 guidance and expects revenues will be in the range of $14 to $18 million in fiscal 2012, inclusive of research funding from Shire. Full Article
Sangamo BioSciences, Inc. Issues FY 2012 Revenue Guidance In Line With Analysts' Estimates
Sangamo BioSciences, Inc. announced that it expects that revenues will be in the range of $14-$18 million in fiscal 2012, inclusive of research funding from Shire. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report revenue of $16 million for fiscal 2012. Full Article
Shire plc And Sangamo BioSciences, Inc. Collaborate To Develop Therapeutics For Treatment Of Hemophilia And Other Monogenic Diseases
Shire plc and Sangamo BioSciences, Inc. announced that they have entered into a collaboration and license agreement to develop therapeutics for hemophilia and other monogenic diseases based on Sangamo's zinc finger DNA-binding protein (ZFP) technology. Shire will receive exclusive world-wide rights to ZFP Therapeutics designed to target four genes (for blood clotting Factors VII, VIII, IX and X) which will be used to investigate curative therapies for hemophilia A and B. Shire also receives the right to designate three additional gene targets. Sangamo is responsible for all activities through submission of Investigational New Drug (IND) Applications and European Clinical Trial Applications (CTA) for each product and Shire will reimburse Sangamo for its internal and external research program-related costs. Shire is responsible for clinical development and commercialization of products arising from the alliance. Shire will pay Sangamo $13 million upfront followed by research, regulatory, development and commercial milestone payments, and royalties on product sales. Full Article
Sangamo BioSciences, Inc. Announces Initiation Of Two New Phase 2 HIV Clinical Trials
Sangamo BioSciences, Inc. announced the initiation of two new Phase 2 clinical studies (SB-728-1101 and SB-728-902, Cohort 5) in its program to develop a functional cure for HIV/AIDS. Sangamo's ZFP Therapeutic approach (SB-728-T) generates T-cells that are resistant to HIV infection using its zinc finger nuclease (ZFN) technology to permanently disrupt the DNA sequence encoding CCR5, a co-receptor used by HIV to enter cells. The Company expects to present data from its SB-728-T HIV clinical trials at appropriate medical meetings in 2012. The new studies employ two approaches to increase the number of engrafted T-cells in which both CCR5 gene copies are modified (biallelically modified) in SB-728-T-treated, HIV-infected subjects. The first, an extension of an ongoing trial (SB-728-902, Cohort 5), is designed to further investigate the effect of SB-728-T treatment on HIV viral load in subjects that are naturally heterozygous for the CCR5 delta-32 gene mutation (i.e. one of their two CCR5 gene copies has the mutation and one is normal). The second study (SB-728-1101), in HIV-infected subjects without the CCR5 delta-32 mutation, employs a conditioning pretreatment designed to significantly enhance the number of engrafted biallelically modified T-cells. Full Article
Sangamo BioSciences, Inc. Announces Publication In Nature Of Gene Correction Strategy For Alpha 1-Antitrypsin Deficiency
Sangamo BioSciences, Inc. announced the publication of a preclinical study demonstrating highly specific, functional correction of the alpha 1-antitrypsin (A1AT) gene defect in patient-derived induced pluripotent stem cells (iPSCs) using zinc finger nucleases (ZFNs). The study, published in Nature, further highlights the precision and broad applicability of ZFN-based genome-editing for the development of ZFP Therapeutics for the treatment of monogenic diseases. The work was carried out in collaboration with scientists at the Wellcome Trust Sanger Institute, the University of Cambridge, U.K., DNAVEC Corporation of Japan, and several laboratories in Europe. The study was published as an Advance Online Publication in Nature on October 12, 2011 (http://www.nature.com/nature/journal/vaop/ncurrent/full/nature10424.html).The paper entitled, "Targeted Gene Correction of Alpha 1-Antitrypsin Deficiency in Induced Pluripotent Stem Cells" describes highly specific and efficient ZFN-mediated correction of a defective human A1AT gene in iPSCs derived from skin cells from individuals with alpha 1-antitrypsin deficiency (A1ATD). The A1AT gene encodes a protein that is made in the liver and protects the lungs and liver from damage. A1ATD is the most common inherited metabolic disease of the liver, and is the result of a single mutation in the A1AT gene. iPSCs can be reprogrammed to develop into a wide range of tissues. Full Article
Sangamo BioSciences, Inc. Announces Phase 2b Trial of SB-509 in Diabetic Neuropathy Did Not Meet Key Study Endpoints
Sangamo BioSciences, Inc. announced that its Phase 2b study (SB-509-901) did not meet its primary or secondary clinical endpoints in subjects with moderate severity diabetic neuropathy (DN) as compared to placebo. SB-509 treatment did not show statistically significant improvements from baseline compared with placebo at 180 days in the primary endpoint, sural nerve conduction velocity (sNCV), the secondary endpoint, neuropathy impairment score in the lower limb (NIS-LL), or intraepidermal nerve fiber density (IENFD). In a pre-specified analysis, a clinically relevant improvement was observed in the mean total LENSE score of 3.4 points in SB-509-treated subjects compared to a 1.9 point improvement in placebo treated subjects from baseline (p=0.11). This trend affected pinprick and touch pressure sensation more than vibration, and was primarily due to improvement seen in subjects with a baseline IENFD score of <9 fibers/mm. In this group the effect on total LENSE score was more prominent at 90 days (mean improvement of 4.3 points in treated subjects compared with a worsening of 0.8 points in placebo subjects; p=0.008) than at 180 days (mean improvement of 4.8 points in treated subjects compared with an improvement of 1.8 points in placebo subjects; p=0.08). Full Article
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
